Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients

Liver International

Volumn 31, Issue 10, 2011, Pages 1525-1532

  Manolakopoulos, Spilios ^a   Striki, Athanasia ^a   Deutsch, Melanie ^a   Mela, Maria ^b   Ketikoglou, Ioannis ^a   Tzourmakliotis, Dimitrios ^b   Manesis, Emanuel K ^c   Papatheodoridis, George V ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b KAT HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adefovir; Chronic hepatitis B; Combination therapy; Creatinine clearance; HBeAg negative; Lamivudine; Renal dysfunction

Indexed keywords

ADEFOVIR; ALBUMIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; UREA; VIRUS DNA;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC DISEASE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERAL CONDITION DETERIORATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PREDICTOR VARIABLE; PROTHROMBIN TIME; RENAL PROTECTION; TREATMENT DURATION; UREA BLOOD LEVEL; VIRULENCE; VIRUS CARRIER; VIRUS DETECTION;

ADENINE; ADULT; AGE FACTORS; AGED; CREATINE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GREECE; HEPATITIS B; HEPATITIS B E ANTIGENS; HUMANS; KIDNEY; LAMIVUDINE; LINEAR MODELS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS;

EID: 80053938419     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02616.x     Document Type: Article

References (24)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
2. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
3. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-9.
4. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-56.
5. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-78.
6. Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57-63.
7. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-26.
8. Manolakopoulos S, Triantos C, Theodoropoulos J, et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol 2009; 51: 468-74.
9. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
10. Manolakopoulos S, Bethanis S, Koutsounas S, et al. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008; 27: 266-73.
11. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-13.
12. Vassiliadis TG, Giouleme O, Koumerkeridis G, et al. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study. J Gastroenterol Hepatol 2010; 25: 54-60.
13. Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004; 66: 1153-8.
14. Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001; 15: 1695-700.
15. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185-95.
16. Ha NB, Garcia RT, Trinh HN, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50: 727-34.
17. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
18. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47.
19. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
20. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
21. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
22. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
23. Gish R, Mangahas M, Baqai S, Shaw R. Risk of renal toxicity with tenofovir Df (Tdf) for Chronic Hepatitis B (Chb). J Hepatol 2010; 52: S388-89.
24. Van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.